AptarGroup (ATR) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $1.52
- Estimate
- $1.47
- Surprise
- +3.3%
- Score at report (before → after)
- 5.1 → 5.2/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
AptarGroup (ATR) beat the $1.47 estimate with adjusted EPS of $1.52 — a clear 3.3% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.1/10) to Sell at 5.2/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ATR Sell at 5.2/10.
4 of the last 4 quarters beat the estimate; this quarter's +3.3% surprise compares with a +3.4% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Concentration risk — Supplier: single-source resins and rubber components
- Thin upside margin: 8.1%
- V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $130.64
- Price target
- $141.16
- Stop
- $125.82
- Upside to target
- +8.1%
- Reward-to-risk
- 0.9:1
At 23.6× trailing and 21.1× forward earnings, consensus estimates imply little change in earnings power.
Risk check: RSI 79 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-10-30 — shown for context, not personalized investment advice.
ATR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Instruments & Supplies
- Market cap
- $8.31B
- P/E (fwd)
- 21.1
- P/E (ttm)
- 23.6
- 52-week range
- $103.23–$146.91
- Off 52-week high
- 11.1%
- RSI (14)
- 79
- Volume vs avg
- 1.34×
- Score today
- 5.2/10